Diffuse infiltrative lung disease, pericarditis, pleural effusion and ceritinib hypersensitivity
Diffuse infiltrative lung disease, pericarditis, pleural effusion and ceritinib hypersensitivity
复制标题
DOI：
10.1016/j.rmr.2019.05.040
复制
发表时间：
2019-09-01
影响因子：
0.6
通讯作者：
Kiakouama-Maleka, L.
中科院分区：
文献类型：
--
作者：
Gaillard, C. -M.;Churnbi-Flores, W.;Kiakouama-Maleka, L.
酪氨酸激酶抑制剂现在是治疗存在ROS 1基因重排的非小细胞转移性肺癌的主要药物。由于这些新疗法的快速发展，开发有关其监测和了解其潜在毒性的信息至关重要。我们描述的情况下，谁是用塞瑞替尼作为三线方法治疗转移性肺腺癌与ROS1重排的患者。两个月后，患者出现急性呼吸窘迫伴心包炎和胸膜炎。在塞瑞替尼停药和全身性皮质类固醇引入后3天内，提示了超敏反应，并得到了有利的临床和放射学结局的支持。与色瑞替尼相关的胸腔积液、心包炎和弥漫性肺浸润以前并不常见。尽管与ceritinib相关的肺毒性数据很少，但目前的观察结果强调了在使用这些抑制剂时需要谨慎和定期监测。(C)2019年SPLF。由Elsevier Masson SAS出版。All rights reserved.
Tyrosine kinase inhibitors are now major actors for the treatment of non-small cell metastatic lung cancers where ROS 1 gene rearrangement is present. Because of the rapid development of these new therapies, developing information about their monitoring and knowledge about their potential toxicities is essential. We describe the case of a patient who was treated with ceritinib as a third line approach for a metastatic lung adenocarcinoma with ROS1 rearrangement. After two months, the patient developed acute respiratory distress with pericarditis and pleurisy. A hypersensitivity reaction was suggested and supported by favorable clinical and radiological outcomes within three days following ceritinib discontinuation and systemic corticosteroid introduction. Pleural effusion, pericarditis and diffuse pulmonary infiltration associated to ceritinib have not often been described previously. Despite few data of pulmonary toxicity related to ceritinib, the current observation highlights the need for caution and regular monitoring when using these inhibitors. (C) 2019 SPLF. Published by Elsevier Masson SAS. All rights reserved.